BioPharma Dive: Ligand Binding Program Considerations — The Value of Preclinical to Clinical Bioanalytical Expertise
Snuggle Wrap-based Restraint Method of Continuous Infusion in Juvenile Nonhuman Primates
Historical Control Database of Cynomolgus Macaque Spermatozoa
Determination of Normal: Flow Cytometry Analysis of Major Immune Cell Populations in Peripheral Blood of Naïve Cynomolgus Monkeys
Assessment of Subcutaneous Radio-Telepathy Device Implantation in Cynomolgus Monkeys
Assessment of Receptor Occupancy via Flow Cytometry: Benefits and Pitfalls of Two Common Approaches
Dedicated Full-Time Experts Working for You!
 |
|
At Altasciences, our full-time equivalent (FTE) solutions give you access to capabilities and expertise tailored to your requirements. Our experts treat your priorities with the same level of commitment to timelines and deliverables as you do. |
 |
 |
Releasing Quality Batches Successfully… The First Time
|
|
You can depend on Altasciences’ highly skilled team to meet the requirements of even your most complex pharmaceutical manufacturing projects. We have the training programs in place to ensure our team completes your project to the highest industry standards. We pride ourselves in releasing quality batches successfully the first time. |
|
|
Our operators are more than just 9 to 5 employees — they are invested in your product. To learn more about our CDMO skilled workforce, contact our experts today. Altasciences’ CDMO site provides pharmaceutical contract development manufacturing and analytical services, including formulation development, Phase I through commercial manufacturing, and ICH stability testing. |
Complimentary Webinar – Latest Trends in Mass Spectrometry Applications
|
|
Passive immunotherapy refers to the transfer of antibodies to an unprotected individual for the treatment or prevention of disease. Monoclonal antibodies (mAbs) offer several advantages as passive immunotherapeutic agents since they can be manufactured at large scale with inherently high specificity and consistency.
In this complimentary presentation, we summarize how we developed a hybrid LC-MRM workflow for the quantitation of mAbs used as passive immunotherapeutic agents of viral infections. The workflow is generic and does not rely on highly specific critical reagents. More importantly, it offers the potential for multiplexing should a combination of different antiviral mAbs be dosed simultaneously. |
|
|